Search Results - "Soerensen, Per"

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers by Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula

“…Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome…”
Get full text

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview by Marrie, Ruth Ann, Cohen, Jeffrey, Stuve, Olaf, Trojano, Maria, Sørensen, Per Soelberg, Reingold, Stephen, Cutter, Gary, Reider, Nadia

“…Background: Comorbidity is an area of increasing interest in multiple sclerosis (MS). Objective: The objective of this review is to estimate the incidence and…”
Get full text

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study by van den Brink, Wim, Sørensen, Per, Torup, Lars, Mann, Karl, Gual, Antoni

“…This study evaluated the long-term efficacy and safety of nalmefene treatment in reducing alcohol consumption. We randomised (1:3) 675 alcohol-dependent…”
Get full text

The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidate by Andersen, Knud Erik, Braestrup, Claus, Groenwald, Frederik C, Joergensen, Anker S, Nielsen, Erik B, Sonnewald, Ursula, Soerensen, Per O, Suzdak, Peter D, Knutsen, Lars J. S

“…A series of different synthetic approaches to novel GABA uptake inhibitors are described, leading to examples which are derivatives of nipecotic acid and…”
Get full text

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper by Otero-Romero, Susana, Sastre-Garriga, Jaume, Comi, Giancarlo, Hartung, Hans-Peter, Soelberg Sørensen, Per, Thompson, Alan J, Vermersch, Patrick, Gold, Ralf, Montalban, Xavier

“…Background and objectives: Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of…”
Get full text

26900 A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI) by Soerensen, Per, Soerensen, Per, Griffiths, Philip, Svane Nielsen, Thor Schüett, Larsen, Lotte Seiding, Resen, Katarina, Prof, Tove Agner

Get full text

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS by Liu, Yawei, Carlsson, Robert, Comabella, Manuel, Wang, JunYang, Kosicki, Michael, Carrion, Belinda, Hasan, Maruf, Wu, Xudong, Montalban, Xavier, Dziegiel, Morten Hanefeld, Sellebjerg, Finn, Sørensen, Per Soelberg, Helin, Kristian, Issazadeh-Navikas, Shohreh

“…Shohreh Issazadeh-Navikas and colleagues report on a previously undescribed population of regulatory T (Treg) cells that accumulate in the CNS in response to…”
Get full text

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364) by Soerensen, Per Soelberg, Dangond, Fernando, Hicking, Christine, Giovannoni, Gavin

“…Abstract only…”
Get full text

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark by Thormann, Anja, Magyari, Melinda, Koch-Henriksen, Nils, Laursen, Bjarne, Sørensen, Per Soelberg

“…To investigate the occurrence of vascular comorbidities before and after the clinical onset of multiple sclerosis. In this combined case–control and cohort…”
Get full text

Demyelination versus remyelination in progressive multiple sclerosis by Bramow, Stephan, Frischer, Josa M., Lassmann, Hans, Koch-Henriksen, Nils, Lucchinetti, Claudia F., Sørensen, Per S., Laursen, Henning

“…The causes of incomplete remyelination in progressive multiple sclerosis are unknown, as are the pathological correlates of the different clinical…”
Get full text

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab by Sørensen, Per Soelberg, Bertolotto, Antonio, Edan, Gilles, Giovannoni, Gavin, Gold, Ralf, Havrdova, Eva, Kappos, Ludwig, Kieseier, Bernd C, Montalban, Xavier, Olsson, Tomas

“…Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS). Treatment with natalizumab has been associated with progressive…”
Get full text

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis by Giovannoni, Gavin, Prof, Cook, Stuart, Prof, Rammohan, Kottil, Prof, Rieckmann, Peter, MD, Sørensen, Per Soelberg, Prof, Vermersch, Patrick, Prof, Hamlett, Anthony, PhD, Viglietta, Vissia, MD, Greenberg, Steven, MD

“…Summary Background On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in…”
Get full text

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS) by Warren, Richard B., French, Lars E., Blauvelt, Andrew, Langley, Richard G., Egeberg, Alexander, Mrowietz, Ulrich, Hunter, Hamish J.A., Gooderham, Melinda, Soerensen, Per, Andres, Philippe, Sommer, Morten O.A., Carlsson, Anna, Kjøller, Kim D., Strober, Bruce E.

“…Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor being investigated as a potential treatment for moderate-to-severe psoriasis. To evaluate…”
Get full text

Effects of Cladribine Tablets on CD4+ T-cell Subsets in the ORACLE-MS Study: Results from an Analysis of Lymphocyte Surface Markers (P1.402) by Leist, Thomas, Stuve, Olaf, Soerensen, Per Soelberg, Hyvert, Yann, Damian, Doris, Boschert, Ursula

“…Abstract only…”
Get full text

Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets (P5.351) by Stuve, Olaf, Soerensen, Per Soelberg, Giovannoni, Gavin, Leist, Thomas, Hyvert, Yann, Damian, Doris, Boschert, Ursula

“…Abstract only…”
Get full text

Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370) by Cook, Stuart, Comi, Giancarlo, Giovannoni, Gavin, Rieckmann, Peter, Soerensen, Per Soelberg, Vermersch, Patrick, Dangond, Fernando, Hicking, Christine

“…Abstract only…”
Get full text

Sea level rise and the sediment budget of an eroding barrier on the Danish North Sea coast by Aagaard, Troels, Soerensen, Per

“…The barrier spit Skallingen on the Danish North Sea coast accreted significantly for a period of three centuries prior to 1970 but it is now strongly eroding…”
Get full text

Very mild to severe dementia and mortality: A 14-year follow-up - The Odense study by Andersen, Kjeld, Lolk, Annette, Martinussen, Torben, Kragh-Sørensen, Per

“…To examine the mortality of very mildly to severely demented persons compared to nondemented persons. Participants in a randomly drawn population-based cohort…”
Get more information

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis by Polman, Chris H, Prof, Bertolotto, Antonio, MD, Deisenhammer, Florian, Prof, Giovannoni, Gavin, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Killestein, Joep, MD, McFarland, Henry F, MD, Oger, Joel, Prof, Pachner, Andrew R, Prof, Petkau, John, Prof, Reder, Anthony T, MD, Reingold, Stephen C, PhD, Schellekens, Huub, Prof, Sørensen, Per Soelberg, Prof

“…Summary The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For…”
Get full text

Survey of diagnostic and treatment practices for multiple sclerosis in Europe by Fernández, O., Delvecchio, M., Edan, G., Fredrikson, S., Gionvannoni, G., Hartung, H.‐P., Havrdova, E., Kappos, L., Pozzilli, C., Soerensen, P. S., Tackenberg, B., Vermersch, P., Comi, G.

“…Background and purpose Up‐to‐date information is needed on the extent to which neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly…”
Get full text